TRANSMEDICS GROUP INC (TMDX)
US89377M1099 - Common Stock
We assign a fundamental rating of 5 out of 10 to TMDX. TMDX was compared to 188 industry peers in the Health Care Equipment & Supplies industry. TMDX has an average financial health and profitability rating. TMDX is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
TMDX had positive earnings in the past year.
In the past year TMDX had a positive cash flow from operations.
In the past 5 years TMDX always reported negative net income.
TMDX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TMDX's Return On Assets of 4.15% is amongst the best of the industry. TMDX outperforms 80.21% of its industry peers.
Looking at the Return On Equity, with a value of 15.55%, TMDX belongs to the top of the industry, outperforming 91.98% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 3.43%, TMDX is in the better half of the industry, outperforming 74.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 15.55% | ||
| ROIC | 3.43% |
ROA(3y)-16.47%
ROA(5y)-20.03%
ROE(3y)-34.23%
ROE(5y)-38.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TMDX's Profit Margin of 8.14% is fine compared to the rest of the industry. TMDX outperforms 79.68% of its industry peers.
The Operating Margin of TMDX (7.84%) is better than 75.40% of its industry peers.
TMDX has a Gross Margin of 59.34%. This is comparable to the rest of the industry: TMDX outperforms 56.15% of its industry peers.
In the last couple of years the Gross Margin of TMDX has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.84% | ||
| PM (TTM) | 8.14% | ||
| GM | 59.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.58%
GM growth 5Y7.7%
2. Health
2.1 Basic Checks
TMDX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, TMDX has more shares outstanding
Compared to 5 years ago, TMDX has more shares outstanding
TMDX has a worse debt/assets ratio than last year.
2.2 Solvency
TMDX has an Altman-Z score of 3.23. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of TMDX (3.23) is better than 67.38% of its industry peers.
TMDX has a Debt/Equity ratio of 2.42. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.42, TMDX is doing worse than 85.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.42 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.23 |
ROIC/WACC0.4
WACC8.57%
2.3 Liquidity
TMDX has a Current Ratio of 8.20. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
TMDX has a better Current ratio (8.20) than 88.24% of its industry peers.
TMDX has a Quick Ratio of 7.33. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.33, TMDX belongs to the top of the industry, outperforming 89.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.2 | ||
| Quick Ratio | 7.33 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 185.45% over the past year.
The Revenue has grown by 109.09% in the past year. This is a very strong growth!
The Revenue has been growing by 79.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)185.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.38%
Revenue 1Y (TTM)109.09%
Revenue growth 3Y111.22%
Revenue growth 5Y79.35%
Sales Q2Q%63.72%
3.2 Future
Based on estimates for the next years, TMDX will show a very strong growth in Earnings Per Share. The EPS will grow by 53.77% on average per year.
Based on estimates for the next years, TMDX will show a very strong growth in Revenue. The Revenue will grow by 34.14% on average per year.
EPS Next Y241.45%
EPS Next 2Y104.7%
EPS Next 3Y76.02%
EPS Next 5Y53.77%
Revenue Next Year90.01%
Revenue Next 2Y54.9%
Revenue Next 3Y42.24%
Revenue Next 5Y34.14%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 84.40, the valuation of TMDX can be described as expensive.
Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than 65.24% of the companies in the same industry.
TMDX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.96.
TMDX is valuated quite expensively with a Price/Forward Earnings ratio of 47.05.
70.59% of the companies in the same industry are more expensive than TMDX, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of TMDX to the average of the S&P500 Index (23.82), we can say TMDX is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 84.4 | ||
| Fwd PE | 47.05 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 66.31% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 57.82 |
4.3 Compensation for Growth
TMDX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TMDX's earnings are expected to grow with 76.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y104.7%
EPS Next 3Y76.02%
5. Dividend
5.1 Amount
No dividends for TMDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TRANSMEDICS GROUP INC
NASDAQ:TMDX (11/21/2024, 8:00:01 PM)
Premarket: 78.01 -1.33 (-1.68%)79.34
+2.14 (+2.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.66B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 84.4 | ||
| Fwd PE | 47.05 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.35
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 15.55% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 7.84% | ||
| PM (TTM) | 8.14% | ||
| GM | 59.34% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.42 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.2 | ||
| Quick Ratio | 7.33 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)185.45%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y241.45%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)109.09%
Revenue growth 3Y111.22%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y